IAN E KROP

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Chemokine signaling in gliomas: prognostic factor, therapeutic target or both?
    IAN E KROP
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 5:1039-41. 2006
  2. doi request reprint A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
    IAN E KROP
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston MA 02215, USA
    J Clin Oncol 30:3234-41. 2012
  3. doi request reprint Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
    IAN E KROP
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Clin Oncol 28:2698-704. 2010
  4. pmc Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists
    Xiuwei H Yang
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute and Harvard Medical School, University of Massachusetts, Boston, Massachusetts, USA
    Cancer Res 70:2256-63. 2010
  5. pmc A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases
    Rachel A Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 11:376-83. 2011
  6. doi request reprint Advances in targeting SRC in the treatment of breast cancer and other solid malignancies
    Erica L Mayer
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 16:3526-32. 2010
  7. doi request reprint Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
    Marta Guix
    Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:897-906. 2008
  8. doi request reprint Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA
    Clin Breast Cancer 13:254-63. 2013
  9. doi request reprint Prevalence of germline TP53 mutations in HER2+ breast cancer patients
    Michelle G Rath
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res Treat 139:193-8. 2013
  10. ncbi request reprint Mechanisms of trastuzumab resistance in breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Anticancer Agents Med Chem 9:348-55. 2009

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Chemokine signaling in gliomas: prognostic factor, therapeutic target or both?
    IAN E KROP
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 5:1039-41. 2006
  2. doi request reprint A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
    IAN E KROP
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston MA 02215, USA
    J Clin Oncol 30:3234-41. 2012
    ....
  3. doi request reprint Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
    IAN E KROP
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Clin Oncol 28:2698-704. 2010
    ..This first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of T-DM1 in patients with advanced HER2-positive breast cancer...
  4. pmc Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists
    Xiuwei H Yang
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute and Harvard Medical School, University of Massachusetts, Boston, Massachusetts, USA
    Cancer Res 70:2256-63. 2010
    ..These new insights should be useful when devising strategies for overcoming drug resistance in ErbB2+ cancers...
  5. pmc A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases
    Rachel A Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 11:376-83. 2011
    ..We observed modest activity with a central nervous system objective response rate of 13.3%; however, median PFS was disappointing. Further studies should focus on other agents to treat this challenging clinical problem...
  6. doi request reprint Advances in targeting SRC in the treatment of breast cancer and other solid malignancies
    Erica L Mayer
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 16:3526-32. 2010
    ..Future trials will continue to explore the contribution of Src inhibition with both chemotherapy and targeted agents...
  7. doi request reprint Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
    Marta Guix
    Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:897-906. 2008
    ....
  8. doi request reprint Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA
    Clin Breast Cancer 13:254-63. 2013
    ..In this retrospective study, we investigated the clinicopathological features associated with prolonged first-line trastuzumab-based treatment duration...
  9. doi request reprint Prevalence of germline TP53 mutations in HER2+ breast cancer patients
    Michelle G Rath
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res Treat 139:193-8. 2013
    ..Given the potential clinical impact, consideration of germline TP53 testing should be given to young women with HER2+ breast cancer, especially if family cancer history is notable...
  10. ncbi request reprint Mechanisms of trastuzumab resistance in breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Anticancer Agents Med Chem 9:348-55. 2009
    ..In this review, we discuss the mechanisms of antitumor activity of trastuzumab, potential mechanisms contributing to its resistance, and novel therapeutic agents that may provide a means to overcome trastuzumab resistance...